Hepatitis C drug sales grew the most

Release time:


The top 50 drugs with the fastest global sales growth in 2015 were up $41 billion million from last year. Gilead's hepatitis C drug Harvoni alone contributed to an increase of $11.7 billion, or 29% of the total increase.
There were 8 drugs with sales growth of more than US $1 billion, of which 3 were hepatitis C drugs, all of which were listed in 2014.
The top 10 fastest-growing drugs combined increased $23 billion, or 56 percent of the total. AbbVie (AbbVie)'s Humira (Humira) and Pfizer (Pfizer)'s Prevnar (Pfizer) are both in the top 10 list of drugs with the fastest sales growth in 2015 and the top 10 list of best-selling drugs in 2015, while the Revlimid of Xinji Pharmaceutical (Celgene) failed to enter the top 10 of sales growth.
Among the top 20 drugs in the sales growth list, it is worth noting some newly listed drugs. In addition to hepatitis C drugs, GlaxoSmithKline (GlaxoSmithKline) listed HIV drugs in 2014 Triumeq an increase of $1 billion. Bristol-Myers PD-1 inhibitor Opdivo, which went public in late 2014, generated $0.942 billion in sales in 2015 (compared to $6 million in 2004). Pfizer's new breast cancer drug, which went on sale in early 2015, gained $0.723 billion, making it 13 on the list.
In the top 50 sales growth list, Roche (Roche) has 5 drugs, a total increase of $1.9 billion; Johnson & Johnson (Johnson & Johnson) has 4 drugs, a total increase of $2 billion. The three drug companies on the list are Bristol-Myers Squibb (growth: $3.4 billion, the same below), AbbVie ($3.3 billion), Novo Nordisk ($1.8 billion), GlaxoSmithKline ($1.8 billion), Xinji Pharmaceutical ($1.5 billion) and Baijian ($1.3 billion). Gilead had only two drugs on the list, but it had the highest increase, at $12.4 billion.
Among these drugs, hepatitis C drugs have increased the most, with $14.7 billion, and cancer drugs have increased by $6.5 billion. In the case of increasing payment pressure in the United States, diabetes drugs still gained an increase of $2.8 billion, and anticoagulants, immunotherapy drugs, and HIV drugs each increased by $2.1 billion.